StockData

Agenus vs Mesoblast

AGEN and MESO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AGEN and MESO compare

Mesoblast grew revenue faster over the last twelve months (599% versus 30.5% for Agenus).

Mesoblast scores higher on the StockData Score (6 against 3 for Agenus), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAGENMESO
Size and price
Market cap$283M–
Share price$6.29$11.91
Change, 1 year45.3%−19.4%
Change, 5 years−90.3%−3.8%
Beta (5Y)1.011.72
Employees81108
StockData Score
Total score36 (better)
Valuation score1 (better)0
Growth score23 (better)
Performance score02 (better)
Health score01 (better)
Dividend score00
Valuation
P/S2.1×–
EV/EBITDA7.0×–
FCF yield−34.8%–
Growth
Revenue growth (TTM)30.5%599% (better)
Revenue growth, 5Y average5.3%74.5% (better)
Profitability
Gross margin99.5% (better)86.1%
Operating margin27.3%–
Net margin–−47.8%
FCF margin−74.2%−37.1% (better)
Financial health
Net debt / EBITDA0.28–
Interest coverage0.6×–
Current ratio0.342.43 (better)
Altman Z-score−16.54–
Piotroski F-score–5
Dividends and buybacks
Shareholder yield0.00%–
Ownership
Held by institutions31.7%0.30%
Held by insiders6.6%37.3%
Insider net buying, 12 months–$37.5M
Short interest, % of float18.1%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.